

AREVIR GOES COLOGNE!!!!

AREVIR-GenaFor-Meeting

Verbundprojekt Monitoring von resistenten HIV bei frisch infizierten und chronisch infizierten HIV-Patienten in Deutschland
EuResist

When: 11.04. – 12.04.13 (9:00 am – 18:30 pm)

Where: ODYSSEUM Köln, Corintostr. 1, 51103 Köln

Registration is free like every year!

We have a restricted number of free rooms for the night from 11. - 12. April for young investigators. Additional rooms and further accommodations are available for special room rates!

Contact:

Claudia.Mueller@med.uni-duesseldorf.de for registration and accommodation

Resistance testing is meanwhile „standard of care“ Different projects such as AREVIR, the „Verbundprojekt Monitoring von resistenten HIV mit RESINA und der RKI Serokonverter-Analyse“ contribute to better interpretation systems and analyze the risk of transmission of resistant HIV in Germany. On a European level the results of AREVIR and RESINA are integrated into the EUResist project together with the Karolinska and ARCA data and recently other European partners (www.euresist.org). Our aim is the prediction of the most likely best working drug combinations. For that reason, geno2pheno-THEO (www.genafor.org) was developed and meanwhile integrated into the EUResist prediction tool which is also freely available via internet. Nevertheless we need to understand the contribution of each resistance associated mutation and we have to agree on strategies for resistance testing and interpretation. These are the aims of HIV-GRADE (www.hiv-grade.de).

New drugs in new classes require equivalent diagnostics. Within HIV-GRADE and geno2pheno such new interpretation tools have been developed. This includes the prediction of the co receptor usage prior to therapy with co receptor blockers like maraviroc and resistance to integrase inhibitors like raltegravir.

For HBV the technical expertise from the HIV-projects could be adapted, so that interpretation systems are already available. Geno2pheno and HIV-GRADE predict resistance, (sub-) genotype and escape mutants. In the near future we will have to deal with resistance to anti-HCV drugs and need appropriate tools for interpretation too.

For HCV-therapy a new era has been entered with the availability of direct antiviral agents (DAAs). The protease inhibitors boceprevir and telaprevir are on the market already and polymerase inhibitors are coming soon. Interpretation systems for the prediction of therapy success are needed and geno2pheno_[HCV] as well as HIV-GRADE are meeting this challenge.

Since 2000 the meeting is an exchange platform for clinicians, bioinformaticians and virologists. Participants have the chance to discuss clinical cases with other experts – the fasta file of the relevant case from HIV, HBV, HCV and clinical information is needed, while the interpretation systems can be utilized online at the meeting. The suppliers of the commercial systems will also be present. Furthermore, protocols are available at the meeting and will be visible on the internet after the meeting under www.genafor.org.

The language of the meeting is English.

Thursday, 11.04.2013

- 09:00- 09:15 **Opening Remarks Thomas Puy-Brill/ Odysseum, Köln**
- 09:15 – 11:15 **State of ART in HBV /HDV - HOPE**
- Chairs:** Ulrike Protzer, Maria Neumann Fraune
- Speakers:** Dieter Glebe, Jens Verheyen, Bastian Beggel, Michael Manns, Florian van Bömmel, Michael Chudy
- 11:15 – 11:45 **Coffee break**
- 11:45 – 13:30 **State of ART in HCV – PEPSI**
- Chairs:** Johannes Bode, Tobias Goeser
- Speakers:** Ralf Bartenschlager, Thomas von Hahn, Anna Marie Sikorski, Stefan Mauss, Christof Sarrazin
- 13:30 – 14:30 **Lunch**
- 14:30 – 15:30 **HIV-1 -2 diagnostics and therapy - state of ART, HIV-2 Algorithm (HIV-GRADE / CHAIN activities)**
- Chairs:** Gerd Fätkenheuer, Stefan Esser
- Speakers:** Diane Descamps/Charlotte Carpentier, Martin Stürmer
- 15:30 – 16:30 **Geno2pheno – the revolution of a concept – basic science and clinical routine**
- Chair:** Thomas Klimkait, n.n.
- Speaker:** Thomas Lengauer and coworkers
- 16:30 – 17:00 **Coffee break**
- 17:00 – 18:00 **Are the current strategies for clinical studies still up to date or yesterdays painful burden?**
- Chairs:** Thomas Lengauer, Mark Oette
- Speakers:** Markus Löffler
- discussion

Friday, 12.04.2013

09:00 – 11:00

EuResist

Chairs:

Francesca Incardona, Eugen Schülter

Speakers:

Francesca Incardona, Maurizio Zazzi, Anders Sonnerborg
Rolf Kaiser: The EucoHIV project

11:00 – 11:30

Coffee break

11:30 – 13:30

RESINA and RKI - seroconverter study

Chairs:

Dieter Häussinger, Herbert Pfister

Speakers:

Mark Oette, Alejandro Pironti, Sybille Somogyi, Klaus Jansen, Björn Jensen, Glenn Lawyer

13:30 – 14:30

Lunch

14:30 – 15:45

Workshop sessions part 1 (select one)

1. HIV-resistance: Stefan Scholten, Alejandro Pironti, Hauke Walter
2. HIV tropism: Björn Jensen, Martin Obermeier, Alexander Thielen
3. HBV resistance and escape: Christof Jochum, Bastian Beggel
4. HCV resistance: Nazifa Qurishi, Nico Pfeifer, Saleta Sierra Aragon

15:45 – 16:30

Coffee break

16:30 – 17:30

Workshop sessions part 2 (select one)

1. HIV-resistance: Stefan Scholten, Alejandro Pironti, Hauke Walter
2. HIV tropism: Björn Jensen, Martin Obermeier, Alexander Thielen
3. HBV resistance and escape: Christof Jochum, Bastian Beggel
4. HCV resistance: Nazifa Qurishi, Nico Pfeifer, Saleta Sierra Aragon

17:30 – 18:00

Summary of the workshops and closing remarks

Rolf Kaiser

The Meeting is kindly supported by:

ViiV Healthcare, Abbott, Roche, Boehringer Ingelheim, Janssen-Cilag GmbH, Bristol-Myers Squibb, Gilead, Siemens, MSD Sharp & Dohme, QIAGEN

The meeting will be certified from the Ärztekammer Nordrhein with credit points.

The Meeting is organised by genafor e.V.

Organising committee:

Björn Jensen, Daniel Hoffmann, Thomas Lengauer, Francesca Incardona, Maurizio Zazzi, Jens Verheyen, Mark Oette, Rolf Kaiser and Claudia Müller

